632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy

Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy

Longitudinal analysis of first and subsequent line tyrosine kinase inhibitor use in chronic myeloid leukemia A 16 year single center experience

Standard tyrosine kinase inhibitor dose versus dose de escalation prior to treatment free remission attempt in chronic myeloid leukemia A single center 25 year retrospective study

Phase II study of clia cladribine idarubicin cytarabine plus tyrosine kinase inhibitor TKI in patients with chronic myeloid leukemia in myeloid blast Phase

Impact CML Indian multicentric data supporting safe pregnancy and molecular control in women with chronic myeloid leukemia

Sequential monitoring using NGS allows detection of ABL1 KD mutations in patients with chronic Phase CML Results from the prospective calls trial

Comparative impact of tyrosine kinase inhibitor dose reduction on ability to achieve treatment free remission among TKI intolerant patients with chronic myeloid leukemia

Prognostic utility of the ELTS score in pediatric chronic myeloid leukemia Is it a valid clinical tool

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia Long term real world evidence on the role of faster molecular decline and duration of response

What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia

Somatic mutations in cancer related genes in chronic myeloid leukemia patients receiving asciminib

Chronic myelogenous leukemia A real world experience from a Los Angeles county safety net hospital

Asciminib ASC demonstrates continued improvement in patient reported outcomes PROs vs investigator selected tyrosine kinase inhibitors IS TKIs in newly diagnosed chronic myeloid leukemia CML ASC4FIRST week 96 analysis

Nanopore sequencing to detect BCR ABL1 and associated genomic rearrangements in CML

Identification of predictive protein signatures of treatment free remission in patients with chronic myeloid leukaemia